Previous 10 | Next 10 |
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes...
YARDLEY, Pa., June 20, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present at the 2019 BMO Capital Markets Pres...
YARDLEY, Pa., June 19, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the Company has been named one of the Philadelphia Business Journal ’s ...
The following slide deck was published by OptiNose, Inc. in conjunction with this Read more ...
The following slide deck was published by OptiNose, Inc. in conjunction with their 2019 Q1 earnings Read more ...
OptiNose, Inc. (OPTN) Q1 2019 Earnings Conference Call May 09, 2019, 08:00 AM ET Company Participants Jonathan Neely - VP, IR & Business Operations Peter Miller - CEO Keith Goldan - CFO Tom Gibbs - Chief Commercial Officer Ramy Mahmoud - President & COO Conference ...
OptiNose (NASDAQ: OPTN ): Q1 Non-GAAP EPS of -$0.70 beats by $0.01 . More news on: OptiNose, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Company reports first quarter 2019 total revenues of $4.5 million. XHANCE first quarter net product revenues grew to $4.0 million XHANCE prescriptions increased 59% from fourth quarter 2018 to first quarter 2019 Conference call and webcast to be held today at 8:00 a.m. Eastern...
YARDLEY, Pa., April 25, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the first quarter 2019, before market open ...
OptiNose, Inc. (OPTN) Q4 2018 Earnings Conference Call March 6, 2019 8:00 AM ET Company Participants Jonathan Neely - Vice President, Investor Relations and Business Operations Peter Miller - Chief Executive Officer Keith Goldan - Chief Financial Officer Tom Gibbs - Chief Comme...
News, Short Squeeze, Breakout and More Instantly...
YARDLEY, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that XHANCE ® (fluticasone propionate) has been added to Express Scripts’ nationa...
YARDLEY, Pa., May 17, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C...
2024-05-15 10:30:03 ET Lake Street analyst issues BUY recommendation for OPTN on May 15, 2024 08:43AM ET. The previous analyst recommendation was Buy. OPTN was trading at $1.13 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...